Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma
Treatments studied
Part of Cancer clinical trials.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old.
- Your cancer must be a type called 'extrapulmonary neuroendocrine carcinoma' (cancer that started outside the lungs) and has come back or not responded to a platinum-based chemotherapy.
- Your cancer must have started in the digestive tract (stomach, esophagus, small intestine, colon, rectum, pancreas, or bile ducts) OR in the urinary/genital area (prostate, bladder, ureter, urethra, or kidney).
- You must have at least one tumor that can be measured on a scan (CT or MRI).
- You must be in reasonably good health, able to walk and take care of yourself, and have adequate organ function (kidneys, liver, blood counts, and heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug, Tarlatamab, for women whose gynecological neuroendocrine cancer has come back or spread. The drug targets a protein on cancer cells to help the immune system attack them. The study aims to see if it can shrink tumors and slow the disease.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
This trial tests a new drug, tarlatamab, which targets a protein called DLL3 found on the surface of certain cancer cells. The goal is to see if it can shrink or control tumors in people with small-cell lung cancer or other poorly differentiated neuroendocrine cancers, and to learn more about who benefits most.
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.